Screener
Monte Rosa Therapeutics, Inc. GLUE Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.
The source filing: Monte Rosa Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:09 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336711
FAQ
- What is Monte Rosa Therapeutics, Inc.'s enterprise value?
- Monte Rosa Therapeutics, Inc. (GLUE) reported enterprise value of $1.99B in Q2 2026.
- How has Monte Rosa Therapeutics, Inc.'s enterprise value changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s enterprise value increased by 656.8% year-over-year, from $263.26M to $1.99B.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s enterprise value?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s enterprise value has grown at a 11.0% compound annual growth rate (CAGR), from $612.81M to $930.35M.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.
Ask your AI about Monte Rosa Therapeutics, Inc.'s enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude